Par Pharmaceutical Inc, a developer, manufacturer and marketer of safe, innovative and cost-effective generic pharmaceutical and branded injectable products, and part of Endo International plc (NASDAQ: ENDP), announced on Wednesday that it has started shipping the generic version of Pfizer's Chantix (varenicline), 0.5mg and 1mg tablets.
The company has taken this step subsequent to the final approval from the United States food and Drug Administration for its Abbreviated New Drug Application.
Jon Holden, senior vice president and general manager, Generics at Endo, said, 'This important approval brings the first Chantix generic to the US market. As a reliable, quality supplier, Par is proud to help people during this critical time while also expanding our product portfolio.'
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling